1st Cardiology Department, University of Athens Medical School, "Hippokration" Hospital, Athens, Greece.
1st Cardiology Department, University of Athens Medical School, "Hippokration" Hospital, Athens, Greece.
Atherosclerosis. 2014 Jan;232(1):10-6. doi: 10.1016/j.atherosclerosis.2013.10.014. Epub 2013 Oct 25.
Metabolic syndrome (MetS) is associated with adverse cardiovascular events, and impaired vascular function. In this study we evaluated the effects of omega-3 polyunsaturated fatty acids (PUFAs) supplementation on vascular function, inflammatory and fibrinolytic process in subjects with MetS.
We studied the effect of a 12 weeks oral treatment with 2 g/day of omega-3 PUFAs in 29 (15 male) subjects (mean age 44 ± 12 years) with MetS on three occasions (day0: baseline, day 28 and day 84). The study was carried out on two separate arms (PUFAs and placebo), according to a randomized, placebo-controlled, double-blind, cross-over design. The diagnosis of MetS was based on the guidelines of Adult Treatment Panel III definition. Endothelial function was evaluated by flow-mediated dilation (FMD) of the brachial artery. Carotid-femoral pulse wave velocity (PWV) was measured as an index of aortic stiffness. Serum levels of interleukin-6(IL-6) and plasminogen activator inhibitor-1(PAI-1) were measured by ELISA.
Treatment with PUFAs resulted in a significant improvement from day 0 to 28 and 84 in FMD and PWV (p < 0.001 for all). Nevertheless, treatment with placebo resulted in no significant changes in FMD (p = 0.63) and PWV (p = 0.17). Moreover, PUFAs treatment, compared to placebo, decreased IL-6 levels (p = 0.03) and increased PAI-1 levels (p = 0.03). Finally, treatment with PUFAs resulted in a significant decrease in fasting triglyceride levels from day 0 to 28 and 84 (p < 0.001) and in serum total cholesterol levels (p < 0.001).
In subjects with MetS, treatment with omega-3 PUFAs improved endothelial function and arterial stiffness with a parallel antiinflammatory effect.
代谢综合征（MetS）与不良心血管事件和血管功能受损有关。在本研究中，我们评估了ω-3 多不饱和脂肪酸（PUFA）补充对 MetS 患者血管功能、炎症和纤溶过程的影响。
我们研究了在 29 名（15 名男性）MetS 患者（平均年龄 44±12 岁）中，每天口服 2gω-3 PUFAs，持续 12 周，在三个时间点（第 0 天：基线、第 28 天和第 84 天）的影响。该研究根据随机、安慰剂对照、双盲、交叉设计，分为两个独立的组别（PUFAs 和安慰剂）进行。MetS 的诊断基于成人治疗小组 III 定义。通过肱动脉血流介导的扩张（FMD）评估内皮功能。颈动脉-股动脉脉搏波速度（PWV）作为主动脉僵硬度的指标进行测量。通过 ELISA 测量血清白细胞介素-6（IL-6）和纤溶酶原激活物抑制剂-1（PAI-1）的水平。
PUFAs 治疗可显著改善 FMD 和 PWV，从第 0 天到第 28 天和第 84 天（均 p <0.001）。然而，安慰剂治疗对 FMD 没有显著影响（p=0.63），对 PWV 也没有显著影响（p=0.17）。此外，与安慰剂相比，PUFAs 治疗降低了 IL-6 水平（p=0.03），增加了 PAI-1 水平（p=0.03）。最后，PUFAs 治疗可显著降低空腹甘油三酯水平，从第 0 天到第 28 天和第 84 天（均 p <0.001）和血清总胆固醇水平（均 p <0.001）。
在 MetS 患者中，ω-3 PUFAs 治疗可改善内皮功能和动脉僵硬，同时具有抗炎作用。
